Karyopharm to Participate in Upcoming Investor Conferences

NEWTON, Mass., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that members of the management team will participate in the following upcoming investor conferences:

• Canaccord Genuity Rare Disease and BioPharma 1x1 Day on Tuesday, February 7, 2017 at the InterContinental Barclay in New York. 
• Leerink Partners 6th Annual Global Healthcare Conference on Thursday, February 16, 2017 at 3:30 p.m. ET at the Lotte New York Palace in New York.

A live webcast of the Leerink presentation can be accessed under "Events & Presentations" in the Investors section of the Company's website at http://investors.karyopharm.com/events.cfm. A replay of the webcast will be archived on the Company's website for 30 days following the presentation.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. Karyopharm's SINE™ compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). The Company's initial focus is on seeking regulatory approval and commercialization of its lead drug candidate, oral selinexor (KPT-330). To date, over 1,900 patients have been treated with selinexor and it is currently being evaluated in several mid- and later-phase clinical trials across multiple cancer indications, including multiple myeloma in combination with low-dose dexamethasone (STORM) and backbone therapies (STOMP), and in acute myeloid leukemia (SOPRA), diffuse large B-cell lymphoma (SADAL), and liposarcoma (SEAL), among others.  Karyopharm plans to initiate a pivotal randomized Phase 3 study of selinexor in combination with bortezomib (Velcade®) and low-dose dexamethasone (BOSTON) in patients with multiple myeloma in early 2017.  In addition to single-agent and combination activity against a variety of human cancers, SINE™ compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm, which was founded by Dr. Sharon Shacham, currently has five investigational programs in clinical or preclinical development. For more information, please visit www.karyopharm.com. 

Contacts:

Justin Renz
(617) 658-0574
[email protected]

Gina Nugent
(617) 460-3579
[email protected]

You May Also Be Interested In

• Monster Energy's Max Alran Takes First Place in Downhill Mountain Bike Race at the 2026 WHOOP UCI Mountain Bike World Series Les Gets
• Top Meme Coin To Buy: Pipedog Selling Persists Despite 3,294% APY as AlphaPepe Stage 20 Keeps Filling
• pixelgrinder Announces Second Full-Length Album “White Mask” for September 25 Release